Confronto

Glepaglutide vs. Linaclotid

Due peptidi a confronto — identità, base di evidenze, stato legale ed eventi avversi noti.

Identità

Categoria

Ricerca (altro)

N. CAS

nessun dato

851199-59-2

Peso molecolare

nessun dato

1526.74 g/mol

Emivita

nessun dato

Sequenza

nessun dato

Meccanismo d'azione

Glepaglutide

As a GLP-2 receptor agonist, glepaglutide has a trophic effect on the intestinal mucosa, enlarging the absorptive surface and thereby improving intestinal uptake of nutrients and fluid.

Linaclotid

Linaclotide activates the guanylate cyclase-C receptor on the luminal surface of the intestinal epithelium. This raises cyclic GMP (cGMP), increases secretion of chloride and bicarbonate into the lumen, raises stool fluid content and accelerates transit; pain signaling is also modulated.

Base di evidenze

Evidenza più alta

RCT sull'uomo

Studi

di cui sull'uomo

Effetti registrati

Contraddizioni aperte

Eventi avversi documentati

Stato legale

Country	Glepaglutide	Linaclotid
Germania	Non approvato	Su prescrizione
Stati Uniti	Non approvato	Su prescrizione

Voci complete

Frequently asked questions

What is the difference between Glepaglutide and Linaclotid?: Glepaglutide is classified as "Ricerca (altro)", while Linaclotid is classified as "Ricerca (altro)". Glepaglutide: Glepaglutide is a long-acting GLP-2 analogue (Zealand Pharma) intended to reduce the need for parenteral support in short bowel syndrome. Linaclotid: Linaclotide is a 14-amino-acid peptide and guanylate cyclase-C (GC-C) agonist. It is approved for irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, Glepaglutide or Linaclotid?: The highest available evidence level is "RCT sull'uomo" for Glepaglutide and "RCT sull'uomo" for Linaclotid. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of Glepaglutide and Linaclotid in Germany and the United States?: Germania: Glepaglutide — Non approvato, Linaclotid — Su prescrizione. Stati Uniti: Glepaglutide — Non approvato, Linaclotid — Su prescrizione. These are factual summaries with source and review date on the individual pages.

Country

Glepaglutide

Linaclotid

Germania

Non approvato

Su prescrizione

Stati Uniti

Non approvato

Su prescrizione

Frequently asked questions

What is the difference between Glepaglutide and Linaclotid?

Glepaglutide is classified as "Ricerca (altro)", while Linaclotid is classified as "Ricerca (altro)". Glepaglutide: Glepaglutide is a long-acting GLP-2 analogue (Zealand Pharma) intended to reduce the need for parenteral support in short bowel syndrome. Linaclotid: Linaclotide is a 14-amino-acid peptide and guanylate cyclase-C (GC-C) agonist. It is approved for irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, Glepaglutide or Linaclotid?

The highest available evidence level is "RCT sull'uomo" for Glepaglutide and "RCT sull'uomo" for Linaclotid. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of Glepaglutide and Linaclotid in Germany and the United States?

Germania: Glepaglutide — Non approvato, Linaclotid — Su prescrizione. Stati Uniti: Glepaglutide — Non approvato, Linaclotid — Su prescrizione. These are factual summaries with source and review date on the individual pages.